Pilocarpine for the treatment of salivary glands’ impairment caused by radioiodine therapy for thyroid cancer

Aframian, Doron J.; Helcer, Monica; Livni, D; Markitziu, A

doi:10.1111/j.1601-0825.2005.01195.x

Cited by 35 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nine studies were randomized controlled trials (one was cross-over with patients as their own controls) [92][93][94][95][96][97][98][99][100] and seven were before and after studies (one controlled) [101][102][103][104][105][106][107]. Seven studies assessed xerostomia [94, 99-102, 104, 105] and nine studies evaluated both xerostomia and salivary flow rate [92, 93, 95-98, 103, 106, 107].…”

Section: Treatment With Pilocarpine After Radiation Therapymentioning

confidence: 99%

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Jensen

Pedersen

Vissink

et al. 2010

Support Care Cancer

226

180

View full text Add to dashboard Cite

There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.

show abstract

Section: Treatment With Pilocarpine After Radiation Therapymentioning

confidence: 99%

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Jensen

Pedersen

Vissink

et al. 2010

Support Care Cancer

226

180

View full text Add to dashboard Cite

show abstract

“…Prevention of the I-131 induced sialadenitis can be done by parasympathomimetic drugs like pilocarpine and sialogogue agents, which accelerate salivary flow and hence radioactive clearance from the salivary glands [7]. However, not all studies advocate the efficacy of this approach [8].…”

Section: Discussionmentioning

confidence: 99%

Salivary gland duct obstruction after radioiodine therapy: a case report

Gillani¹,

Imran²,

Naeem³

2018

EJMCR

View full text Add to dashboard Cite

Background: Radioiodine therapy has long been used in the treatment of hyperthyroid patients. Salivary complications secondary to radioactive iodine (RAI) treatment are well documented, there is little in the literature addressing salivary gland duct obstruction. We present a rare case of salivary gland duct obstruction developed 2 months after RAI treatment. Case Presentation: We describe a 50-year-old male, treated with RAI for hyperthyroidism. He developed pain and swelling in the left submandibular region, 2 months after receiving RAI treatment (25 mCi). His salivary gland scintigraphy was done after injecting 370 MBq (15 mCi) of Tc99m pertechnetate in supine position. It revealed retention of radiotracer in the left submandibular gland with no drainage through the duct system, even on giving lemon stimulus, favoring submandibular gland duct obstruction. Conclusion: We report this rare complication of submandibular gland duct injury occurring after RAI therapy. The occurrence of this complication even after low dose of radioiodine administration may be listed in gamut. All necessary measures must be taken to reduce such potential complications.

show abstract

“…To demonstrate a further use of pilocarpine, Aframian et al 17 published a study demonstrating the efficacy of a single 5 mg dose of pilocarpine to increase stimulated and non-stimulated salivary flow in five patients with thyroid cancer who underwent adjuvant radioiodine therapy at least three months before the study. The results showed a significantly increased stimulated and nonstimulated salivary flow in four patients; there were no changes in the systolic and diastolic blood pressure, the pulse or body temperature.…”

Section: Discussionmentioning

confidence: 99%

Pilocarpina no tratamento de xerostomia em pacientes submetidos à iodoterapia: estudo piloto

Almeida¹,

Kowalski²

2010

Braz. j. otorhinolaryngol. (Impr.)

View full text Add to dashboard Cite

Xerost omia complaint is very commonly associated to radioactive iodine therapy. Alternatives to treat this morbidity can offer better quality of life to patients with thyroid cancer submitted to adjuvant iodine therapy.Aim: to report on the experience with pilocarpine on the treatment of xerostomia in thyroid cancer patients submitted to adjuvant radioactive iodine therapy (RIT). Materials and methods:The five patients who met the inclusion criteria received 5mg of pilocarpine, 3 tid for one week. Side effects of the drug and subjective response to xerostomia complaints after treatment were evaluated.Design: it is a prospective, non-randomized study.Results: Sudoresis was the most frequent side effect of pilocarpine use, followed by fatigue and headache. Two patients reported relief of xerostomia using pilocarpine, but only one patient was able to tolerate the side effects. Conclusions:Pilocarpine seems to relieve xerostomia complaints in thyroid cancer patients because it is able to stimulate salivary flow, but the observed side effects made the patients refuse long-term therapy continuation. Braz J Otorhinolaryngol. 2010;76(5):659-62. ORIGINAL ARTICLE BJORL

show abstract

Pilocarpine for the treatment of salivary glands’ impairment caused by radioiodine therapy for thyroid cancer

Abstract: Treatment with pilocarpine hydrochloride may be beneficial in the case of impaired salivary function in patients treated with radioiodine.

Cited by 35 publications

References 20 publications

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Salivary gland duct obstruction after radioiodine therapy: a case report

Pilocarpina no tratamento de xerostomia em pacientes submetidos à iodoterapia: estudo piloto

Contact Info

Product

Resources

About